| 1. |
Management of paraprotein disorders causing renal injury |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1400,
2003,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 2. |
Hasty use of stem cell therapies may threaten the field |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1400,
2003,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 3. |
Linezolid potentially less costly than teicoplanin in Gram-positive infections |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1400,
2003,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 4. |
Net savings with doxorubicin liposomal in ovarian cancer |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1400,
2003,
Page 5-5
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 5. |
Bimosiamose*reduces the late asthmatic response in patients with allergic asthma, |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1400,
2003,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 6. |
Treatment using a protein A immunoadsorption column appears effective in severe pemphigus, |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1400,
2003,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 7. |
GM-CSF may reduce viral rebound during interruption of HAART |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1400,
2003,
Page 9-9
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 8. |
Flumazenil may improve the symptoms of Parkinson's disease, |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1400,
2003,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 9. |
Aprepitant: novel antiemetic brings greater benefit for chemotherapy recipients |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1400,
2003,
Page 11-13
RM Poole,
Preview
|
|
摘要:
The addition of the oral substance P/neurokinin-1 (NK1) receptor antagonist aprepitant ['Emend'] to standard antiemetic therapy gives improved control of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy, according to studies presented at the 39th Annual Meeting of the American Society of Clinical Oncology (ASCO) [Chicago, US; May−June 2003]. Analyses of data from two phase III studies showed that aprepitant, when given in combination with the serotonin3receptor antagonist ondansetron and the corticosteroid dexamethasone, reduced the impact of chemotherapy-induced nausea and vomiting on patients' daily lives. Importantly, aprepitant demonstrated efficacy among women and younger patients, two patient subgroups with an increased likelihood of developing nausea and vomiting after chemotherapy.
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 10. |
Better glycaemic control with insulin glargine plus glimepiride |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1400,
2003,
Page 13-13
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
首页
